Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Jon C. Ogg | Apr 5, 2013 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

Jon OggInvestors and traders are usually on the hunt for new ideas that will generate positive returns or income. 24/7…

Douglas A. McIntyre | Apr 4, 2013 at 7:05 AM EDT

How the U.S. Is Making the Rest of the World Fat

ThinkstockPeople who live in nations where most residents were thin, at least as measured against the tremendous number of obese…

Jon C. Ogg | Apr 3, 2013 at 9:20 AM EDT

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Jon OggBoston Scientific Corp. (NYSE: BSX) is in a long-term turnaround that frankly just feels like it never really has…

Jon C. Ogg | Mar 28, 2013 at 8:50 AM EDT

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

ThinkstockMuch of the research coverage on Wall St. from the bulge bracket firms is concentrated on the most liquid, best…

Jon C. Ogg | Mar 27, 2013 at 4:16 PM EDT

Another Major MS Approval Keeps Driving Biogen Idec

ThinkstockShares of Biogen Idec Inc. (NASDAQ: BIIB) did not just do well on Wednesday. The stock hit an all-time high.…

Jon C. Ogg | Mar 27, 2013 at 12:05 PM EDT

Aastrom Implosion Could Have Been Even Worse

ThinkstockAastrom Biosciences Inc. (NASDAQ: ASTM) has just joined in on the long list of biotech implosions. Perhaps the only thing…

Jon C. Ogg | Mar 27, 2013 at 10:50 AM EDT

Chelsea Therapeutics Rally — Speculation or Desperation?

Jon OggChelsea Therapeutics International Ltd. (NASDAQ: CHTP) is rallying on Wednesday after a report in Seeking Alpha called its Northera, a…

Jon C. Ogg | Mar 27, 2013 at 8:50 AM EDT

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ThinkstockAccording to the Center for Disease Control (CDC), more than one-third (35.7%) of all adults in the United States are…

Jon C. Ogg | Mar 26, 2013 at 7:35 AM EDT

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

ThinkstockZIOPHARM Oncology Inc. (NASDAQ: ZIOP) is on implosion watch. The small-cap biotech is indicated to be way down on a…

Jon C. Ogg | Mar 25, 2013 at 10:50 AM EDT

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

ThinkstockSarepta Therapeutics Inc. (NASDAQ: SRPT) should have received a huge boost from “The Barron’s Effect” on Monday. The financial publication,…

Jon C. Ogg | Mar 20, 2013 at 9:00 AM EDT

Model N Sets Up for Strong IPO Debut

ThinkstockInvestors always seem to be on the lookout for initial public offerings. The newest IPO coming to market is Model…

Paul Ausick | Mar 19, 2013 at 8:30 AM EDT

Affymax Stares into the Face of Oblivion

ThinkstockAfter the markets closed last night, drugmaker Affymax Inc. (NASDAQ: AFFY) said that it would cut 230 workers (75% of…

Jon C. Ogg | Mar 11, 2013 at 9:20 AM EDT

Omthera Pharmaceuticals Files for IPO

ThinkstockOmthera Pharmaceuticals has joined the wave of companies wanting to come public. Omthera is a clinical stage biotech and will…

Jon C. Ogg | Mar 8, 2013 at 9:00 AM EST

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

ThinkstockPharmacyclics Inc. (NASDAQ: PCYC) has had a monster stock performance, with gains of much more than 200% over the past…

Jon C. Ogg | Mar 5, 2013 at 11:40 AM EST

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

ThinkstockNymox Pharmaceutical Corp. (NASDAQ: NYMX) took a mystery beating last Friday, to the point that a single stock circuit breaker was triggered…

1 … 305 306 307 308 309 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

How the U.S. Is Making the Rest of the World Fat

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

Another Major MS Approval Keeps Driving Biogen Idec

Aastrom Implosion Could Have Been Even Worse

Chelsea Therapeutics Rally — Speculation or Desperation?

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

Model N Sets Up for Strong IPO Debut

Affymax Stares into the Face of Oblivion

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

Health and Healthcare Articles

All Health and Healthcare Articles

Top Analyst Upgrades and Downgrades (CELG, CMCSA, FB, FFIV, JPM, JNPR, KMB, NWSA, PDCE, AET, CI, HUM, UNH, WLP)

How the U.S. Is Making the Rest of the World Fat

Boston Scientific Downgrade — Valuation or Turnaround Risk?

Top Biotech-Pharma Stock Ideas With Continued Big Upside (OREX, HALO, BAX, BMRN)

Another Major MS Approval Keeps Driving Biogen Idec

Aastrom Implosion Could Have Been Even Worse

Chelsea Therapeutics Rally — Speculation or Desperation?

Merrill Lynch Picks Diabetes Drug Makers as Real Winners (MRK, BMY, LLY, NOV, MNKD, BAC)

ZIOPHARM Joins Biotech Implosion Watch After Sarcoma Failure

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

Model N Sets Up for Strong IPO Debut

Affymax Stares into the Face of Oblivion

Omthera Pharmaceuticals Files for IPO

Pharmacyclics Does Smart and Opportunistic Capital Raise After Huge Run Up

Nymox Tries for Recovery on Safety Profile of NX-1207 for Prostate Cancer

This High-Yield Bond ETF Offers Steady Cash Flow and Low Volatility

This Natural Resources ETF Has Silently Outperformed The S&P 500 Year-To-Date While Yielding 5%

XRP vs Solana vs Ethereum: Which Altcoin is the Best Buy for Upside Right Now?

Featured Reads

39% of Americans Are Betting on Crypto and Prediction Markets Instead of Saving

A $300,000 Annuity Guarantees $1,900 a Month for Life, but Here Is What Retirees Are Giving Up